. 2022 Feb 18;10(2):327. doi: 10.3390/vaccines10020327

Table 2.

Characteristics of patients on hemodialysis at time point of first vaccination and their further serological responses throughout the following 24 weeks.

Variable	All	Non-Responder	Insufficient Responder	Responder	Subgroup Comparison	Correlation with Anti -SARS-CoV-2 IgG 24 Weeks after 1st Vac
Variable	MD [Q1;Q3], (Range: Min–Max) or n (% of Subgroup)
Patients	59	12	28	19	NA	NA
Gender, n (%)	♀ 22 (37.3%)	♀ 6 (50.0%)	♀ 7 (25.0%)	♀ 9 (47.4%)	p = 0.156 °	0.112, p = 0.401 ^‡
Gender, n (%)	♂ 37 (62.7%)	♂ 6 (50.0%)	♂ 21 (75.0%)	♂ 10 (52.6%)	p = 0.156 °	0.112, p = 0.401 ^‡
Age, years	68 [59; 77],	76 [66; 78],	68 [57; 76],	62 [54; 70],	p = 0.034 *	−0.411; p < 0.001 ^†
Age, years	(50–90)	(63–85)	(53–83)	(50–90)	p = 0.034 *	−0.411; p < 0.001 ^†
Body Mass Index, kg/m²	27.1 [22.4; 30.3],	27.6 [23.5; 30.3],	26.8 [21.5; 29.9],	27.0 [23.5; 31.6],	p = 0.819 *	0.037; p = 0.786 ^†
Body Mass Index, kg/m²	(17.9–46.3)	(19.0–36.7)	(18.4–42.8)	(17.9–46.3)	p = 0.819 *	0.037; p = 0.786 ^†
Dialysis vintage, years	4 [2; 12],	4 [1; 10],	4 [2; 9],	4 [1; 26],	p = 0.892 *	0.118; p = 0.376 ^†
Dialysis vintage, years	(0–46)	(0–46)	(0–31)	(0–38)	p = 0.892 *	0.118; p = 0.376 ^†
HepB- vac responders	16 (27.1 %)	2 (16.7 %)	6 (21.4 %)	8 (42.1 %)	p = 0.239 °	0.268; p = 0.042 ^†
Diabetes mellitus	29 (49.2 %)	7 (58.3 %)	13 (46.4 %)	9 (47.4 %)	p = 0.838 °	−0.256; p = 0.053 ^†
C-reactive Protein, mg/dL	3.4 [1.8; 9.4],	4.9 [2.4; 22.6],	4.5 [2.0; 10.7],	2.3 [0.9; 4.5],	p = 0.036 *	−0.319; p = 0.015 ^†
C-reactive Protein, mg/dL	(<0.4–60.7)	(2.2–22.6)	(0.6–60.7)	(<0.4–11.2)	p = 0.036 *	−0.319; p = 0.015 ^†
Leukocytes, e³/µL	6.7 [5.6; 8.0],	6.8 [5.7; 9.4],	6.8 [5.4; 8.1],	6.6 [5.8; 7.8],	p = 0.729 *	−0.081; p = 0.544 ^†
Leukocytes, e³/µL	(1.6–11.7)	(5.3–11.7)	(1.6–11.0)	(4.3–10.7)	p = 0.729 *	−0.081; p = 0.544 ^†
Vitamin D, ng/mL	23.4 [16.2; 32.0],	15.2 [11.0; 22.6],	24.3 [16.5; 30.5],	27.0 [20.8; 35.0],	p = 0.015 *	0.361; p = 0.006 ^†
Vitamin D, ng/mL	(9.4–45.7)	(9.4–37.9)	(9.6–45.7)	(15.4–45.3)	p = 0.015 *	0.361; p = 0.006 ^†
Serum albumin, g/dL	3.9 [3.8; 4.2],	3.7 [3.1; 3.9],	3.9 [3.8; 4.2]	4.2 [3.9; 4.3],	p = 0.007 *	0.466; p < 0.001 ^†
Serum albumin, g/dL	(2.6–4.5)	(2.6–4.3)	(3.5–4.4)	(3.6–4.5)	p = 0.007 *	0.466; p < 0.001 ^†
Kt/V	1.47 [1.22; 1.70],	1.45 [1.13; 1.67],	1.45 [1.19; 1.66],	1.58 [1.24; 1.92],	p = 0.564 *	0.168; p = 0.207 ^†
Kt/V	(0.91–2.19)	(0.99–1.81)	(0.91–2.05)	(0.94–2.19)	p = 0.564 *	0.168; p = 0.207 ^†
Parathormone, pmol/L	19.3 [11.5; 30.3],	22.5 [14.2; 32.2],	18.8 [14.0; 30.2],	14.8 [8.2; 27.3],	p = 0.706 *	−0.121; p = 0.367 ^†
Parathormone, pmol/L	(1.1–59.7)	(3.4–42.6)	(4.7–46.2)	(1.1–59.7)	p = 0.706 *	−0.121; p = 0.367 ^†
Hemoglobin, g/dL	11.5 [10.8; 12.6],	10.9 [10.4; 11.9],	11.3 [11.0; 12.2],	12.1 [11.2; 12.7],	p = 0.104 *	0.219; p = 0.098 ^†
Hemoglobin, g/dL	(9.2–13.9)	(10.0–13.9)	(9.2–13.7)	(10.5–13.3)	p = 0.104 *	0.219; p = 0.098 ^†

Non-responder = anti-SARS-CoV-2 IgG < 33.8 BAU/mL and neutralizing antibody titer < 1:20; insufficient responder = anti-SARS-CoV-2 IgG ≥ 33.8 BAU/mL but neutralizing antibody titer efficacy < 1:20; responder = anti-SARS-CoV-2 IgG ≥ 33.8 BAU/mL and neutralizing antibody titer ≥ 1:20; vac = vaccination; MD = median; Q1 = 1st quartile; Q3 = 3rd quartile; n = count; NA = not applicable; * = Kruskal–Wallis test; ° = Fisher’s exact test; ^‡ = Eta(n) correlation coefficient; ^† = Spearman’s correlation coefficient.